Breakthrough candida infection in a preterm infant with congenital cutaneous Candida albicans infection

American Journal of Perinatology

Volumn 22, Issue 3, 2005, Pages 169-172

  Adler, Amos ^a,b   Litmanovitz, Ita ^a,b   Regev, Rivka ^a,b   Arnon, Shmuel ^a,b   Bauer, Sophia ^a,b   Dolfin, Tzipora ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Amphotericin B; Antifungal susceptibilities testing; Congenital cutaneous candidiasis; Fluconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; BETAMETHASONE; FLUCONAZOLE; GENTAMICIN; MEROPENEM; OXYGEN; SURFACTANT;

ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDIASIS; CASE REPORT; CONGENITAL INFECTION; CRYOTHERAPY; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; INFANT; MALE; MINIMUM INHIBITORY CONCENTRATION; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RETROLENTAL FIBROPLASIA; SEPSIS; SKIN CULTURE; SKIN INFECTION; THORAX RADIOGRAPHY;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; BACTEREMIA; CANDIDIASIS; CANDIDIASIS, CUTANEOUS; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; MALE; MICROBIAL SENSITIVITY TESTS; PREGNANCY;

EID: 17844398965     PISSN: 07351631     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864855     Document Type: Article

References (20)

1. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:258-291
2. Khoory BJ, Vino L, Dall'agnola A, Fanos V. Candida infections in newborn: a review. J Chemother 1999;11:367-378
3. Freidman S, Richardson SE, Jacobs SE, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000;19:499-504
4. Rowen JL, Tate JM. Management of neonatal candidiasis. Pediatr Infect Dis J 1998;17:1007-1011
5. Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000;28:223-226
6. Scarcella A, Pasquariello MB, Giugliano B, Vendemmia M, De Lucia A. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17: 146-148
7. Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed 2001;84:F131-F133
8. Hann IM, Prentice HG. Lipid based amphotericin B: a review of the last 10 years of use. Int J Antimicrob Agents 2001;17:161-169
9. Krcmery V, Huttova M, Mateicka M, et al. Breakthrough fungemia in neonates and infants caused by Candida albicans and Candida parapsilosis susceptible to fluconazole in vitro. J Antimicrob Chemother 2001;48:521-525
10. Darmstadt GL, Dinulos JG, Miller Z. Congenital cutaneous candidiasis: clinical presentation, pathogenesis and management guidelines. Pediatrics 2000;105:438-444
11. Krcmery V, Oravacova E, Spanik S, et al. Nosocomial breakthrough fungemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology, risk factors and outcome. J Antimicrob Chemother 1998;41:373-380
12. Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002;21:209-211
13. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999;340: 764-771
14. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with Liposomal Amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-234
15. Hong Nguyen M, Peacock JE, Morris AJ, et al. The changing face of candidemia: emergence on non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-623
16. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-P Villanova, PA: National Committee for Clinical Laboratory Standards; 1992
17. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 1997;24:235-247
18. Perea A, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002;35:1073-1080
19. Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998;177:425-430
20. Huang YC, Kao HT, Lin TY, Kuo AJ. Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia. Am J Perinatol 2001;18: 141-146